Kymera Therapeutics (KYMR) Net Equity Issued and Repurchased (2020)

Kymera Therapeutics' (KYMR) quarterly Net Equity Issued and Repurchased came in at $83.4 million in Q4 2020, up 200.0% on a QoQ basis from -$83.4 million in Q3 2020.

Kymera Therapeutics (KYMR) Net Equity Issued and Repurchased (2020) Analysis & Trends

Kymera Therapeutics (KYMR) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $83.4 million in Q4 2020.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $83.4 million in Q4 2020; TTM through Dec 2020 was $88.2 million, a N/A change from a year earlier, with the FY2020 full-year figure at $88.2 million, up 528.74% from the prior year.
  • Net Equity Issued and Repurchased for Q4 2020 stood at $83.4 million, up from -$83.4 million in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for KYMR reached as high as $88.2 million in Q1 2020 and fell as low as -$83.4 million in Q3 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Kymera Therapeutics 10.77 Bn 10.11 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 83.38 Mn
Dec 31, 2020 83.38 Mn
Sep 30, 2020 -83.38 Mn
Sep 30, 2020 -83.38 Mn
Jun 30, 2020 -19,000.00
Jun 30, 2020 -19,000.00
Mar 31, 2020 88.20 Mn
Mar 31, 2020 88.20 Mn